Trial Details
RecruitingBasic Information
| Clinical ID | c2043 |
|---|---|
| Identifier | NCT06599658 |
| Trial Title | The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | COVID 19;Influenza;Rheumatoid Arthritis (RA);Systemic Lupus Erthematosus;Inflammatory Bowel Disease;Solid Organ Transplant Recipients;Immunocompromised Host;People Living With HIV |
| Interventions | Biological: Inactivated influenza vaccine (IIV) at baseline;Biological: COVID-19 Vaccines at a 3-month interval;Biological: Inactivated influenza vaccine at Month 1;Biological: COVID-19 Vaccines at a 6-month interval |
Participant Information
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
|---|---|
| City | - |
| Country/Region | Canada |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |